No Data
Biopharmaceutical Research Company (BRC) Announces Development and Regulatory Milestone Following Successful Type C CMC Meeting With FDA, Advancing Clinical Development of Multiple Therapeutic Candidates
Truist Removes Price Target From BRC Inc. on Volatility, Low Share Price, Keeps Hold Rating; Prior Price Target Was $4
Truist Financial Maintains BRC Inc(BRCC.US) With Hold Rating
Truist Financial Remains a Hold on BRC (BRCC)
Roth MKM Maintains BRC Inc(BRCC.US) With Hold Rating, Cuts Target Price to $3.5
BRC Inc's Energy Requires Front-loaded Marketing Spend, Says Roth MKM
